KhaledSanberMDPhD

PubMed

• Divergent clinical and immunologic outcomes based on STK11 co-mutation status in resectable KRAS-mutant lung cancers following neoadjuvant immune checkpoint blockade.
  Samuel Rosner, Sydney Connor, Khaled Sanber, Marianna Zahurak, Tianbei Zhang
  Clinical Cancer Research. 2024-11-15
• Outcome of adult acute myeloid leukemia patients with extramedullary disease and treatment with venetoclax/hypomethylating agents.
  Sabine Kayser, Khaled Sanber, Giovanni Marconi, Agnese Mattei, Marlise R Luskin
  Haematologica. 2024-10-03
• 8 citations
  Autologous HER2-specific CAR T cells after lymphodepletion for advanced sarcoma: a phase 1 trial.
  Meenakshi Hegde, Shoba Navai, Christopher DeRenzo, Sujith K Joseph, Khaled Sanber
  Nature Cancer. 2024-06-01

Books/Book Chapters

• Chimeric Antigen Receptor T-Cell Therapies for Cancer 
  Chapter: Chapter 12 - CAR T-Cell Therapy for CNS Malignancies 
  Page 165 - 198Khaled Sanber, Sujit K. Joseph, Nabil AhmedEditors: Daniel W. Lee and Nirali N. Shah.ElsevierEdition 1,2020
• Fitzpatrick's Dermatology 
  Chapter: Chapter 191: Antiviral Drugs 
  Zeena Y. Nawas; Quynh-Giao Nguyen; Khaled S. Sanber; Stephen K. TyringEditors: Sewon Kang, Masayuki Amagai, Anna L. Bruckner, Alexander H. Enk, David J. Margolis, Amy J. McMichael, Jeffrey S. Orringer.McGraw HillEdition 9th,

Abstracts/Posters

• Predicting Risk of Clinical Deterioration: A Closer Look at Resident Handoffs and Rapid Response
  Sanber K, Jacobson R, Tuthill S, Kaul B, Hemmige V, Guy E, Shah C, Greenberg S, ACP Associates Day; Society for General Internal Medicine (SGIM) Meeting, Houston, TX, 2018; Washington, DC, 2019, 1/1/2019
• Radiation priming improves the anti-tumor activity of HER2 CAR T cells in glioblastoma.
  Mullikin D, Joseph SK, Mathew P, Vita S, Byrd T, Sanber K, Krishnamurthy P, Lindsay H, Chakraborty R, Gaber MW, Ahmed N, Hegde M, American Society for Pediatric Hematology/Oncology (ASPHO) Conference, New Orleans, LA, 1/1/2019
• SHP2: sailing against tumor-mediated inhibition of chimeric antigen receptor T-cell therapy
  Sanber K, Nawas Z, Landi D, Lee C, Sengal A, Chakraborty R, Brunetti L, Sujith J, Mukherjee M, Ahmed N, Hegde M, Multiple presentations, Mutiple locations, 2017, 2018, 2019, 1/1/2019
• Improving efficiency and safety of MICU transfers
  Emge D, Tuthill S, Sanber K, Shieh M, Wu E, Kapoor S, American College of Physicians (ACP) Meeting, Denver, CO, 1/1/2018
• A Tale of two opportunistic infections
  Kampangkaew J, Millien V, Chen S, Sanber K, Sargsyan Z, Society of General Internal Medicine (SGIM) Southern Regional Meeting, New Orleans, LA, 1/1/2017
• A clinical-grade constitutive packaging cell line for the production of selfinactivating lentiviral vectors. Human Gene Therapy
  Sanber K, Knight S, Stephen S, Bailey R, Escors D, Minshull J, Santilli G, Thrasher A, Collins M, Takeuchi Y, Human Gene Therapy; British Society for Gene and Cell Therapy (BSGCT) Congress; European Society for Gene and Cell Therapy (ESGCT) Congress, London, United Kingdom, 2013; The Hague, Netherlands, 2014, 1/1/2014
• Join now to see all

Lectures

• SHP2: sailing against tumor-mediated inhibition of chimeric antigen receptor T-cell therapy 
  Houston, TX - 1/1/2019
• Administration of HER2-CAR T cells after lymphodepletion safely improves T cell expansion and induces clinical responses in patients with advanced sarcomas 
  Atlanta, GA - 1/1/2019
• Predicting Risk of Clinical Deterioration: A Closer Look at Resident Handoffs and Rapid Response 
  Houston, TX - 1/1/2019
• Malignancy-Associated Hemophagocytic Lymphohistiocytosis: An Emerging Problem Needing Urgent Solutions 
  New Orleans, LA - 1/1/2018
• Join now to see all

Other

• Production of self-inactivating lentiviral vectors by constitutive packaging cell lines for gene therapy clinical applications 
  Sanber K, University College London
  London, United Kingdom - 1/1/2014